14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Price (Quote)

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $3.02 $6.17 Friday, 27th May 2022 CATB stock ended at $3.36. This is 6.16% more than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 6.65% from a day low at $3.16 to a day high of $3.37.
90 days $3.02 $7.25
52 weeks $1.20 $10.26

Historical Catabasis Pharmaceuticals prices

Date Open High Low Close Volume
Sep 24, 2019 $5.87 $5.88 $5.12 $5.19 164 522
Sep 23, 2019 $6.03 $6.16 $5.66 $5.66 48 662
Sep 20, 2019 $6.07 $6.34 $5.98 $6.00 207 361
Sep 19, 2019 $5.93 $6.08 $5.93 $6.05 14 937
Sep 18, 2019 $6.01 $6.13 $5.86 $5.92 20 729
Sep 17, 2019 $6.07 $6.17 $5.88 $6.00 19 276
Sep 16, 2019 $5.91 $6.12 $5.87 $6.01 8 920
Sep 13, 2019 $6.06 $6.19 $5.90 $6.03 29 060
Sep 12, 2019 $6.43 $6.52 $6.00 $6.00 61 622
Sep 11, 2019 $6.14 $6.36 $6.14 $6.36 20 751
Sep 10, 2019 $6.04 $6.21 $6.03 $6.10 28 791
Sep 09, 2019 $6.02 $6.19 $5.77 $6.03 50 011
Sep 06, 2019 $6.15 $6.28 $5.97 $6.00 24 820
Sep 05, 2019 $6.32 $6.32 $6.09 $6.09 28 767
Sep 04, 2019 $6.20 $6.39 $6.10 $6.33 20 535
Sep 03, 2019 $6.11 $6.40 $6.10 $6.39 14 549
Aug 30, 2019 $6.21 $6.35 $6.15 $6.17 19 666
Aug 29, 2019 $6.28 $6.47 $6.12 $6.31 45 299
Aug 28, 2019 $6.37 $6.55 $6.31 $6.55 14 053
Aug 27, 2019 $6.80 $6.89 $5.94 $6.28 65 208
Aug 26, 2019 $6.81 $6.87 $6.52 $6.85 28 382
Aug 23, 2019 $6.60 $6.80 $6.52 $6.68 14 910
Aug 22, 2019 $7.08 $7.08 $6.41 $6.71 43 861
Aug 21, 2019 $6.60 $7.30 $6.60 $7.01 70 251
Aug 20, 2019 $6.46 $6.60 $6.36 $6.60 25 265
Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT